Slingshot Biosciences, Inc. Partners With Kem-En-Tec Nordic A/S to Distribute Synthetic Cells Throughout Denmark, Sweden, Norway, Finland, and Iceland
16.6.2022 10:00:00 EEST | Business Wire | Press release
SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Kem-En-Tec Nordic A/S, Provider of Competent Bioscience products to the Nordic laboratories since 1987.
The agreement entitles Kem-En-Tec Nordic A/S to the right to distribute and resell Slingshot Bio’s products in Denmark, Sweden, Norway, Finland, and Iceland. Through Kem-En-Tec Nordic A/S’s network of customers, Slingshot Bio will be able to establish its presence in the Nordic market with the well-established presence and expertise of Kem-En-Tec Nordic A/S which has been selling into flow cytometry for many years.
“Kem-En-Tec Nordic A/S’s network will provide us with the market penetration needed to reach our full sales potential. Slingshot Biosciences has considered many distribution partners and we are confident that Kem-En-Tec Nordic A/S’s extensive knowledge in the field, prominent presence, and large customer base will help us leverage our position in the flow cytometry market,” said Jeffrey Kim, CEO & Founder.
Slingshot Bio’s synthetic cellular controls provide consistent, precise, and accurate control for research users in the flow cytometry space by mimicking blood properties as detected by flow cytometry. The ability to manufacture consistent controls for flow cytometry has been missing for decades and is now accurately reproducible with Slingshot Bio’s unique manufacturing platform. “Kem-En-Tec Nordic strongly believes that the innovative synthetic cell controls from Slingshot will be widely adopted by researchers using flow cytometry in all the Nordic countries,” said Henrik Tind Nielsen, CCO & Co-Owner at Kem-En-Tec Nordic.
About Slingshot Biosciences, Inc.
Founded in 2012, Slingshot Biosciences is a fast-growing life sciences company with a platform technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based applications—including diagnostics, and adoptive cell therapy development and instrument calibration. Learn more at www.slingshotbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614006014/en/
Contact information
Slingshot Biosciences, Inc.
The Synthetic Cell Company
1250 45th St. Suite 330
Emeryville, CA 94608
510-770-6806
www.slingshotbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coulson Aviation Defines the Next Chapter of Innovation With EmberWorks10.9.2026 15:03:00 EEST | Press release
Coulson Aviation is moving forward with EmberWorks, its dedicated innovation division created to turn real-world operational challenges into new capabilities for aerial firefighting, aviation, and emergency response. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910644135/en/ Comparison imagery demonstrates how ORBIT uses airborne thermal sensing and automated processing to identify wildfire activity and generate geolocated fire intelligence. First introduced at the Aerial Fire Fighting Global Conference in Rome earlier this year, EmberWorks formalizes an approach to innovation that has existed throughout Coulson’s history. From aircraft modification and mission-system development to programs such as C-130 airtanker, Boeing 737 Fireliner, and CH-47 Chinook helicopter, Coulson has long developed solutions in response to real-world operational needs. EmberWorks builds on that history by giving this approach a dedicated str
Radisys Launches V.AI Ecosystem to Accelerate Telecom AI Service Innovation10.9.2026 15:00:00 EEST | Press release
Radisys® Corporation, a global leader in open telecom solutions, today announced the launch of its V.AI ecosystem, bringing together applications, development tools and leading voice and speech AI technologies to help telecom operators create, deploy and monetize AI-powered communication services for consumers and business subscribers. The V.AI ecosystem, which has evolved since the launch of the Radisys Engage Digital Platform (EDP) at MWC Barcelona in 2022, draws on two decades of Radisys leadership in real-time media processing and a global footprint across live operator networks. Seamlessly integrated with EDP, the ecosystem gives operators multiple paths to market. Operators can deploy turnkey applications, customize services for specific markets and customer segments, or create new device-independent, network-delivered experiences through V.AI Studio, Radisys’ development environment for voice and video AI services. Charter members of the V.AI ecosystem, ElevenLabs, Hiya, ReadSpe
BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology10.9.2026 15:00:00 EEST | Press release
BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910717829/en/ BioLife offers a new solution for oral GLP-1 delivery The announcement comes as demand for GLP-1 medicines continues to accelerate. GLP-1 therapies generated approximately $132 billion in global sales in 2025, while obesity medicines now represent an estimated $42 billion market.1 As more patients seek alternatives to injections, demand for alternative oral treatments continues to grow. First generation oral GLP-1 medicines have demonstrated the value of oral administration while also underscoring on the fundamental challenges in peptide drug development: protecting large peptide molecule
Netskrt to Showcase Media Over QUIC Work with Oracle at IBC 202610.9.2026 15:00:00 EEST | Press release
Netskrt, an independent content delivery network built for high-concurrency streaming events, today announced that it will showcase its work to advance Media Over QUIC (MOQ) at IBC 2026, taking place Sept. 11-14 at RAI Amsterdam. As part of the event, Netskrt will demonstrate with Oracle how independently operated CDN infrastructure can participate in a coordinated MOQ delivery path designed to bring live media closer to viewers. MOQ is an emerging IETF effort designed to support low-latency media delivery at scale, with live streaming among its primary use cases. Its relay-based architecture enables media to move through distributed infrastructure closer to audiences, creating new possibilities for reducing latency while efficiently serving highly concurrent live events. At IBC, Netskrt and Oracle will put that model into practice. An Oracle Video Edge (OVE) containerized relay running within Netskrt infrastructure will coordinate with Oracle’s relay network as part of an end-to-end M
Bending Spoons enters into a definitive agreement to acquire Miro for $1.355 billion10.9.2026 15:00:00 EEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has entered into a definitive agreement to acquire Miro at an enterprise value of $1.355 billion. Together with Miro’s net cash, this implies an equity value of approximately $1.79 billion. In connection with the all-cash transaction, certain Miro shareholders have agreed to invest $295 million of their proceeds into newly issued Bending Spoons equity. The acquisition, including the investment, is subject to customary closing conditions and approvals, including regulatory approvals. “It's a privilege, and no small responsibility, to welcome a product that over 250,000 organizations have integrated into their workflows,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Miro has grown to around $600 million in annual recurring revenue, nearly 90% from business and enterprise customers. After closing, we plan to invest substantially in the fundamentals that its customers value: performance, reliability, and functionality that supports critical col
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom